Cargando…

Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report

Posterior reversible encephalopathy syndrome (PRES) is a disorder of reversible subcortical vasogenic brain oedema in patients with acute neurological symptoms. Drug‐induced PRES has been described with the usage of drugs that target receptors regulating vascular permeability or altering immune resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Abhishek, Mahajan, Renuka, Ashtekar, Ujjwal, Agarwal, Amit, Choudhari, Vijay, Patil, Vanita, Noronha, Nandini, Menon, Kumar, Prabash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458498/
https://www.ncbi.nlm.nih.gov/pubmed/35243821
http://dx.doi.org/10.1002/cnr2.1605
_version_ 1784786309480448000
author Abhishek, Mahajan
Renuka, Ashtekar
Ujjwal, Agarwal
Amit, Choudhari
Vijay, Patil
Vanita, Noronha
Nandini, Menon
Kumar, Prabash
author_facet Abhishek, Mahajan
Renuka, Ashtekar
Ujjwal, Agarwal
Amit, Choudhari
Vijay, Patil
Vanita, Noronha
Nandini, Menon
Kumar, Prabash
author_sort Abhishek, Mahajan
collection PubMed
description Posterior reversible encephalopathy syndrome (PRES) is a disorder of reversible subcortical vasogenic brain oedema in patients with acute neurological symptoms. Drug‐induced PRES has been described with the usage of drugs that target receptors regulating vascular permeability or altering immune response. Lenvatinib is a receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor receptors implicated in cancer progression in addition to their normal cellular functions. The oedema associated with PRES is a consequence of disruption of cerebral blood flow autoregulation. Herein, we present a case of a 77‐year‐old lady who was on treatment with Lenvatinib for metastatic thyroid cancer who subsequently developed PRES. Her clinical and radiological findings improved after discontinuing Lenvatinib and the patient was switched to a different drug and remains asymptomatic on the same. This is the first such report of atypical findings of PRES in a patient on Lenvatinib therapy. Recognition of this entity is crucial for timely withdrawal of the drug and prevent further morbidity and mortality.
format Online
Article
Text
id pubmed-9458498
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-94584982022-09-12 Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report Abhishek, Mahajan Renuka, Ashtekar Ujjwal, Agarwal Amit, Choudhari Vijay, Patil Vanita, Noronha Nandini, Menon Kumar, Prabash Cancer Rep (Hoboken) Case Reports Posterior reversible encephalopathy syndrome (PRES) is a disorder of reversible subcortical vasogenic brain oedema in patients with acute neurological symptoms. Drug‐induced PRES has been described with the usage of drugs that target receptors regulating vascular permeability or altering immune response. Lenvatinib is a receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor receptors implicated in cancer progression in addition to their normal cellular functions. The oedema associated with PRES is a consequence of disruption of cerebral blood flow autoregulation. Herein, we present a case of a 77‐year‐old lady who was on treatment with Lenvatinib for metastatic thyroid cancer who subsequently developed PRES. Her clinical and radiological findings improved after discontinuing Lenvatinib and the patient was switched to a different drug and remains asymptomatic on the same. This is the first such report of atypical findings of PRES in a patient on Lenvatinib therapy. Recognition of this entity is crucial for timely withdrawal of the drug and prevent further morbidity and mortality. John Wiley and Sons Inc. 2022-03-03 /pmc/articles/PMC9458498/ /pubmed/35243821 http://dx.doi.org/10.1002/cnr2.1605 Text en © 2022 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Abhishek, Mahajan
Renuka, Ashtekar
Ujjwal, Agarwal
Amit, Choudhari
Vijay, Patil
Vanita, Noronha
Nandini, Menon
Kumar, Prabash
Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report
title Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report
title_full Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report
title_fullStr Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report
title_full_unstemmed Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report
title_short Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report
title_sort atypical posterior reversible encephalopathy syndrome associated with lenvatinib therapy in a patient with metastatic thyroid cancer—a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458498/
https://www.ncbi.nlm.nih.gov/pubmed/35243821
http://dx.doi.org/10.1002/cnr2.1605
work_keys_str_mv AT abhishekmahajan atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport
AT renukaashtekar atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport
AT ujjwalagarwal atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport
AT amitchoudhari atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport
AT vijaypatil atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport
AT vanitanoronha atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport
AT nandinimenon atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport
AT kumarprabash atypicalposteriorreversibleencephalopathysyndromeassociatedwithlenvatinibtherapyinapatientwithmetastaticthyroidcanceracasereport